C26 Stock Chart & Stats
€16.36
-€0.36(-1.99%)
At close: 4:00 PM EST
€16.36
-€0.36(-1.99%)
Day’s Range― - ―
52-Week Range€10.64 - €17.06
Previous CloseN/A
Volume0.00
Average Volume (3M)6.00
Market Cap
€320.75M
Enterprise Value€3.13K
Total Cash (Recent Filing)€172.19M
Total Debt (Recent Filing)€52.27M
Price to Earnings (P/E)26.5
Beta0.68
Next Earnings
Oct 29, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding23,851,547
10 Day Avg. Volume20
30 Day Avg. Volume6
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.58Price Target Upside-17.02% Downside
Rating ConsensusHold
Number of Analyst Covering1
EPS Forecast (FY)0.57
Revenue Forecast (FY)€70.91M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet And Low LeverageExtremely low leverage and materially higher equity provide durable financial flexibility. This conservatism supports R&D spending, absorbs working-capital swings and funds regulatory/commercial investments without needing external financing, reducing long-term financial risk.
High And Durable Profitability MarginsStrong gross and operating margins reflect differentiated product economics and recurring software/reagent mix, supporting consistent cash generation. High margins create room for reinvestment and competitive resilience, underpinning sustainable returns across cycles.
Product Pipeline And Commercial Traction (Bone Marrow, FPM)CEVI’s Bone Marrow application and FPM platform represent structural product expansion. Successful U.S. 510(k) clearance and platform commercialization would open new clinical use cases, expand consumable/software recurring revenue and lift medium-term addressable market.
Bears Say
TTM Revenue And Margin DecelerationTrailing‑twelve‑month revenue and margin erosion indicate a pause in prior momentum. If persistent, this reduces operating leverage and cash generation, pressuring reinvestment capacity and return metrics until new product launches or regional recovery restore growth.
APAC / China UnderperformanceWeakness in APAC, especially China, highlights geographic concentration risk and uneven end‑market recovery. Prolonged underperformance in a major region would limit global growth and could require higher commercial investment to regain traction, weighing on margins.
Free-cash-flow Volatility And Working-capital SensitivityFluctuating free cash flow and quarter‑level working capital swings reduce predictability of funds for R&D, dividends or M&A. Even with strong operating margins, cash volatility raises execution risk and may force conservative capital allocation until cash conversion stabilizes.
CellaVision AB News
C26 FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was €10.64 and its highest was €17.06 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is €320.75M.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Oct 29, 2026 which is in 98 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Jul 17, 2026. The company reported €0.124 earnings per share for the quarter, beating the consensus estimate of €0.121 by €0.003.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB does not currently pay dividends.
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 0.13.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of €0.124 in its last earnings report, beating expectations of €0.121. Following the earnings report the stock price went up 0.828%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in DE:C26
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
C26 Stock 12 Month Forecast
Average Price Target
€13.58
▼(-17.02% Downside)
Technical Analysis
BICO Group AB Class B
―
Senzime AB
―
Xvivo Perfusion AB
―
C-Rad AB Class B
―
Sedana Medical AB
―